Clinical Research Directory
Browse clinical research sites, groups, and studies.
Monotherapy of an NMDA Enhancer for Schizophrenia
Sponsor: China Medical University Hospital
Summary
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2018-01-01
Completion Date
2027-12
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
NMDAE
Use of an NMDA enhancer for the treatment of schizophrenia
Placebo Cap
Use of placebo as a comparator
Locations (1)
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan